Marco Ruella: So excited to see our discovery make it into human trials!
Marco Ruella, Assistant Professor Of Medicine and Scientific Director Lymphoma Program at University of Pennsylvania, shared the following by Vittoria Biotherapeutics, on LinkedIn, adding the following:
“So excited to see our discovery make it into human trials! thanks to Nicholas Siciliano and the whole team to make it happen! see our work at Ash23 Ruchi Patel Adam Snook abstracts 3462 and 102!”
Quoting Vittoria Biotherapeutics:
“We’re thrilled to announce we received FDA clearance on our IND application for our VIPER-101 candidate, as a potential treatment for T-cell Lymphoma patients. Today’s news underscores a significant achievement, as Vittoria transitions to a clinical stage company and moves one step closer to bringing life changing solutions to patients. To learn more, read here.”
Source: Marco Ruella/LinkedIn and Vittoria Biotherapeutics/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023